Abstract:Background: Individuals infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), have increased risk of cardiovascular diseases (CVD). Endothelial dysfunction, characterized in part by a reduction in the vasodilatory molecule nitric oxide (NO), is a primary mechanism of CVD and has been observed in people with COVID-19. However, it is not well known if alterations in the circulating milieu (i.e., plasma) contribute to COVID-19-associated endothelial dysfunction. Moreover, the mechanisms by which circulating factors may contribute to endothelial dysfunction in COVID-19, including increased reactive oxygen species (ROS)-related oxidative stress and depletion of the key metabolic co-substrate nicotinamide adenine dinucleotide (NAD + ), remain to be determined. Purpose: Here, we tested the hypotheses that circulating factors in plasma from patients with COVID-19 would cause ex vivo endothelial cell dysfunction (reduced acetylcholine-stimulated NO production), increase ROS bioactivity and decrease NAD + levels. We also assessed whether the NAD + precursor nicotinamide riboside (NR) would prevent endothelial cell dysfunction and oxidative stress induced by circulating factors in plasma from patients with COVID-19. Methods: Plasma samples were obtained from the University of Colorado Anschutz Medical Campus COVID-19 Biobank Specimen Repository. Samples were from men and women (age 18+ years) who were hospitalized and tested positive (+; n=34) or negative (–; n=13) for COVID-19. Human aortic endothelial cells (HAECs) in culture were exposed to 10% subject plasma, then stained with florescent probes to detect NO production (DAR-4M AM; before and 6 minutes after addition of 100μM acetylcholine), as an ex vivo model of endothelial function, and basal ROS bioactivity (CellROX), as a mechanism modulating endothelial cell function. NAD + and NADH were measured in cells after plasma exposure using luminescence-based detection. HAECs exposed to COVID-19+ plasma also were co-incubated with 1mM NR. Results: Acetylcholine-stimulated NO production was lower (-27±12%; mean±SD; p<0.0001), and ROS bioactivity was higher (54±41%; p=0.0002), in HAECs exposed to plasma from COVID-19+ vs. COVID-19– individuals. Total NAD + (12.4±1.8 vs. 17.7±8.0au; p=0.0013) and NAD + /NADH (4.2±1.6 vs. 5.6±1.8au; p=0.0167) were lower in HAECs exposed to plasma from COVID-19+ vs. COVID-19– individuals. However, when HAECs exposed to plasma from COVID-19+ individuals were treated with NR, acetylcholine-stimulated NO production and ROS bioactivity were not different from that of HAECs exposed to plasma from COVID-19– individuals (all p>0.05). Conclusions: These findings suggest that circulating factors promote COVID-19-related endothelial cell dysfunction, increase ROS bioactivity and lead to NAD + depletion. Supplementation with NAD + precursors, such as NR, may be an effective strategy to prevent endothelial dysfunction and reduce the risk of CVD with COVID-19. F31HL154782, 3R01AG061514-02S2, K01DK115524 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Dysregulated nicotinamide adenine dinucleotide metabolome in patients hospitalized with COVID‐19

SARS-CoV-2 infection dysregulates NAD metabolism

Circulating factors in plasma from patients with COVID-19 cause endothelial cell dysfunction, oxidative stress and NAD+ depletion: prevention by nicotinamide riboside

NAD+-boosting compounds enhance nitric oxide production and prevent oxidative stress in endothelial cells exposed to plasma from patients with COVID-19

COVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?

Association of NAD+ levels with metabolic disease in a community-based study

The Serum Metabolome of COVID-19 Patients is Distinctive and Predictive

Uneven metabolic and lipidomic profiles in recovered COVID‐19 patients as investigated by plasma NMR metabolomics

Serum nitrite and nitrate: A potential biomarker for post-covid-19 complications?

Nicotinamide Adenine Dinucleotide Metabolome Is Functionally Depressed in Patients Undergoing Liver Transplantation for Alcohol-Related Liver Disease

Decoding NAD+ Metabolism in COVID-19: Implications for Immune Modulation and Therapy

COVID-19 infection results in alterations of the kynurenine pathway and fatty acid metabolism that correlate with IL-6 levels and renal status

Integrative Plasma Metabolic and Lipidomic Modelling of SARS-CoV-2 Infection in Relation to Clinical Severity and Early Mortality Prediction

Efficiency of Nicotinamide-Based Supportive Therapy in Lymphopenia for Patients with Ordinary or Severe COVID-19: A Randomized Controlled Trial.

Metabolic predictors of COVID-19 mortality and severity: a survival analysis

Synergy Between NK Cells and Monocytes in Potentiating Cardiovascular Disease Risk in Severe COVID-19

Metabolic Indicators Associated with Non-Communicable Diseases Deteriorated in the Coronavirus Disease 2019 Outbreak: Evidence from a Two-Center, Retrospective, Self-Controlled Study

Metabolomic profiling of COVID-19 using serum and urine samples in intensive care and medical ward cohorts

Longitudinal Metabolomics Reveals Ornithine Cycle Dysregulation Correlates With Inflammation and Coagulation in COVID-19 Severe Patients

In Vivo and Ex Vivo Mitochondrial Function in COVID-19 Patients on the Intensive Care Unit

Increased Oxidative Stress and Decreased Citrulline in Blood Associated with Severe Novel Coronavirus Pneumonia in Adult Patients